Detalles de la búsqueda
1.
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Esophagus
; 20(2): 281-289, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484900
2.
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
Br J Cancer
; 124(5): 914-924, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33299131
3.
Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Oncologist
; 26(4): e588-e596, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33325566
4.
CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
Int J Clin Oncol
; 26(9): 1628-1639, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34117553
5.
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
Int J Cancer
; 145(12): 3414-3424, 2019 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31087550
6.
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.
Cancer Sci
; 110(1): 52-60, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30390416
7.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Gastric Cancer
; 21(1): 84-95, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28497176
8.
Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Esophagus
; 20(2): 290, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36658273
9.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Int J Cancer
; 141(8): 1682-1689, 2017 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28677116
10.
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Cancer Sci
; 107(12): 1843-1850, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27712015
11.
Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial.
Cancer
; 122(7): 1050-9, 2016 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26828788
12.
A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.
Invest New Drugs
; 31(3): 599-604, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22623066
13.
Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.
Thorac Cancer
; 14(2): 214-217, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495048
14.
Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Clin Lung Cancer
; 24(6): 519-527.e4, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37344331
15.
Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Lung Cancer
; 174: 71-82, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36347190
16.
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Clin Cancer Res
; 28(2): 390-403, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921025
17.
Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L).
Lung Cancer
; 168: 38-45, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477147
18.
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Int J Clin Oncol
; 16(3): 244-9, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21243395
19.
HER2-/HER3-Targeting Antibody-Drug Conjugates for Treating Lung and Colorectal Cancers Resistant to EGFR Inhibitors.
Cancers (Basel)
; 13(5)2021 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33801379
20.
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.
Clin Cancer Res
; 27(20): 5697-5707, 2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34365406